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Abstract
Plasmodium parasites must control cysteine protease activity that is critical for hepatocyte invasion by sporozoites, liver
stage development, host cell survival and merozoite liberation. Here we show that exoerythrocytic P. berghei parasites
express a potent cysteine protease inhibitor (PbICP, P. berghei inhibitor of cysteine proteases). We provide evidence that it
has an important function in sporozoite invasion and is capable of blocking hepatocyte cell death. Pre-incubation with
specific anti-PbICP antiserum significantly decreased the ability of sporozoites to infect hepatocytes and expression of PbICP
in mammalian cells protects them against peroxide- and camptothecin-induced cell death. PbICP is secreted by sporozoites
prior to and after hepatocyte invasion, localizes to the parasitophorous vacuole as well as to the parasite cytoplasm in the
schizont stage and is released into the host cell cytoplasm at the end of the liver stage. Like its homolog falstatin/PfICP in P.
falciparum, PbICP consists of a classical N-terminal signal peptide, a long N-terminal extension region and a chagasin-like C-
terminal domain. In exoerythrocytic parasites, PbICP is posttranslationally processed, leading to liberation of the C-terminal
chagasin-like domain. Biochemical analysis has revealed that both full-length PbICP and the truncated C-terminal domain
are very potent inhibitors of cathepsin L-like host and parasite cysteine proteases. The results presented in this study
suggest that the inhibitor plays an important role in sporozoite invasion of host cells and in parasite survival during liver
stage development by inhibiting host cell proteases involved in programmed cell death.
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Introduction
Malaria is caused by apicomplexan parasites of the genus
Plasmodium. The infection of the vertebrate host begins with the
inoculation of sporozoites into the dermis during blood feeding of
an infected Anopheles mosquito [1,2,3,4,5,6,7]. Sporozoites traverse
through different cell types [8,9,10,11,12] until they reach the liver
via the bloodstream and finally invade hepatocytes. Here within 2
to 16 days, depending on the Plasmodium species, they develop
inside a parasitophorous vacuole to several thousand red blood
cell-infective merozoites [13]. Using the rodent malaria model
parasite P. berghei, it was shown that infected hepatocytes are
protected against apoptosis throughout liver stage development
[14,15,16]. However, at the end of the liver stage, the parasite
induces an unusual form of programmed cell death that facilitates
the merozoites leaving the liver and gaining access to the
bloodstream [16,17]. Even during this complex liberation process,
which includes parasite-dependent host cell death, classical host
cell apoptosis is not induced and cell membrane integrity is
maintained [16], suggesting that parasite molecules responsible for
inhibition of apoptosis are translocated to the host cell cytoplasm,
at least during this last phase of parasite development in
hepatocytes.
As in the blood stage and mosquito stage [18,19], it was shown
that cysteine proteases play a crucial role in the infection of the
liver by Plasmodium sporozoites [20,21], in parasite development in
liver cells and in the liberation of the fully developed liver
merozoites [16]. Therefore, a tight regulation of protease activity is
critical for the survival of the parasite throughout its life cycle.
Additionally, intra- and extracellular Plasmodium parasites are
exposed to host cell proteases and it is likely that they have evolved
mechanisms to counteract proteolytic digestion.
Host cell proteases are often involved in pathogen defense
mechanisms and a number of other parasites have already been
shown to express cysteine protease inhibitors that block these
proteases. These include host cell proteases involved in antigen
presentation, cytokine responses and host cell apoptosis and
proteases that are stored in potentially fusogenic organelles like
lysosomes and are liberated upon pathogen recognition
[22,23,24,25,26,27,28,29,30,31,32,33,34].
Short-term regulation of parasite as well as host proteases can
be mediated by specific parasite-derived inhibitors. A prominent
example is chagasin, which is expressed by Trypanosoma cruzi and
was the first identified member of a new superfamily of reversible,
tight-binding cysteine protease inhibitors [35]. Structurally similar
inhibitors were found in Trypanosoma brucei, Pseudomonas aeruginosa,
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Leishmania mexicana, Leishmania major, Entamoeba histolytica, P.
falciparum and Toxoplasma gondii [36,37,38,39,40,41,42,43]. Chaga-
sin-like inhibitors (also termed ICPs for inhibitor of cysteine
proteases) are suggested to regulate both endogenous parasite-
derived cysteine proteases (T. brucei, T. cruzi, P. falciparum, E.
histolytica) and/or host cell proteases (L. mexicana, P. aeruginosa, P.
falciparum) [35,37,38,39,40,41,42,44,45,46].
The P. falciparum ICP (PfICP), termed falstatin, has been
described previously for the blood stage of the human malaria
parasite [40]. Falstatin/PfICP has been characterized as a potent
inhibitor of various parasite and host cell cysteine proteases and is
expressed by blood schizonts, merozoites and rings but not in
trophozoites. Incubation of late schizonts with neutralizing
antibodies against falstatin/PfICP partially blocked subsequent
invasion of erythrocytes by merozoites, suggesting that regulation
of cysteine protease activity is important for this process.
Here we report on the falstatin homolog of the rodent malaria
parasite P. berghei, which we name PbICP for Plasmodium berghei
inhibitor of cysteine proteases, following the common nomencla-
ture for the entire inhibitor family. PbICP appears to play a critical
role at least during the parasite liver and blood stages in the
vertebrate host. We analyzed specifically the exoerythrocytic
parasite stages and suggest a function of PbICP in sporozoite
invasion and host cell survival.
Materials and Methods
Experimental animals
Animals were obtained from Charles River Laboratories. All
animal work was conducted in compliance with regulations
created and approved by the ethical committee of Hamburg state
authorities (Nr. FI 28/06).
Sequence alignments and expression and purification of
recombinant PbICP proteins
Homology searches, multiple alignments and secondary struc-
ture predictions were performed with public BLAST search tools
(PlasmoDB), the Clustal W program (EMBL-EBI) and structure
prediction programs (PredictProtein, Jpred).
The pbicp gene (full length, PlasmoDB: PB000502.02.0), pbicp-n
and pbicp-c were amplified from cDNA of P. berghei ANKA
wildtype mixed blood stage parasites using the following primer
pairs: PbICP-fw (59-GG GAATTCGAAGATAACGACATA-
TACTCTTTTGATATC-39) / PbICP-rv (59- CCCAAGCTT T-
TATTGGACAGTCACGTATATAAT-39) to clone MBP-PbICP
full length, PbICP-C-fw1 (59-TTGAATTCGGAGATGAAAAA-
TGTGGTAAATCA-39) / PbICP-C-rv1 (59-TTGGATCC TTA-
TTGGACAGTCACGTATATAAT-39) to clone MBP-PbICP-C,
PbICP-C-fw2 (59- TTCATATG GGAGATGAAAAATGTGG-
TAAATCA-39) / PbICP-C-rv2 (59-TTGAATTC TTATTGGA-
CAGTCACGTATATAAT-39) to clone His-PbICP-C and
PbICP-C without tag, PbICP-N-fw1 (59-GGGAATTCGAAGA-
TAACGACATATACTCTTTTGATATC-39) / PbICP-N-rv1
(59-TT GGATCC TGGTTAAATGAGTTGTATGAAGTAGT-
TGGG -39) to clone MBP-PbICP-N for antibody production,
PbICP-N-fw2 (59-GGGAATTCGAAGATAACGACATATACT-
CTTTTGATATC-39) / PbICP-N-rv2 (59-TTGGATCC AGT-
CAATTCATATTTACTATCAACTTTACCA -39) to clone
MBP-PbICP-N for protease assays.
The PCR products were cloned into the bacterial expression
vectors (pJC25 for untagged PbICP-C, derivative of pJC20 [47];
pJC45 for N-terminal His10-tagged PbICP-C [48]; pMAL-cRI for
N-terminal MBP tagged full length PbICP, PbICP-C and PbICP-
N) using the appropriate restriction enzymes (New England
Biolabs) and clones were analyzed by sequencing. Untagged
PbICP-C and His-PbICP-C were expressed in the BL21 (DE3)
pAPlacI E. coli strain [48] and purified using a MonoQ column
(Pharmacia) or Ni-NTA resin (Qiagen), respectively. MBP-PbICP
(full length), MBP-PbICP-C and MBP-PbICP-N were expressed in
the BL21 E. coli strain (Stratagene) and purified using amylose
resin (New England Biolabs). The MBP-tag of PbICP (full length)
was removed by factor Xa (New England Biolabs) and untagged
PbICP was purified by using a MonoQ column (Pharmacia).
Protease assays
Cathepsin L [49], papain (Sigma) or falcipain-2 [50] were
incubated with 600 mM Z-Phe-Arg-pNA substrate (Bachem) in the
presence or absence of indicated amounts of the recombinant
purified proteins. Assay buffers were 100 mM acetate buffer,
1 mM DTT, pH 5.0 for cathepsin L and 100 mM acetate buffer,
10 mM DTT, pH 5.5 for papain and falcipain-2. Cathepsin B
(Sigma) was incubated with 600 mM Z-Arg-Arg-pNA substrate
(Bachem) in the presence or absence of the indicated amounts of
the recombinant purified proteins in 100 mM KH2PO4, 2 mM
EDTA, 10 mM DTT, pH 6.0. Photometric product formation (E)
was measured every 10 seconds and activity was calculated from
the linear part of the graph (DE/Dt). Protease activity in the
presence of the control protein MBP was set to 100% and residual
activity in the presence of recombinant PbICP constructs was
calculated.
Duplex-PCR
Total RNA was isolated from 106 wildtype oocyst sporozoites,
66105 wildtype salivary gland sporozoites, infected HepG2 cells at
different time points after infection or from saponin-treated
(0,05%, Sigma) blood stage parasites using the RNA Extract Kit
II (Macherey and Nagel). First strand cDNA synthesis was
performed with the SuperscriptTM First-Strand Synthesis System
for RT-PCR (Invitrogen).
Duplex-PCR was performed with the two primer pairs PbICP-
fw (59-ATGCTCCATCCTAGCCCTTT-39) / PbICP-rev (59-
CCACTTTCATTCATTGTGTTGTT-39) and Pbtubulin-fw (59-
TGGAGCAGGAAATAACTGGG-39) / Pbtubulin-rev (59-AC-
CTGACATAGCGGCTGAAA-39). All RNA preparations were
free of genomic DNA (gDNA) contamination as no PCR product
Author Summary
Plasmodium sporozoites are transmitted by Anopheles
mosquitoes to the vertebrate host. They migrate through
the skin before entering blood vessels and being
transported with the bloodstream to liver sinusoids. There
the sporozoites transmigrate through Kupffer cells and
several hepatocytes before they invade a final hepatocyte
and develop into thousands of merozoites. These daugh-
ter parasites are transported inside host cell-derived
vesicles (merosomes) back to the bloodstream where they
are finally released and infect red blood cells. Most of these
processes depend on the activity of proteases, which must
be tightly controlled to avoid proteolytic destruction of the
parasite. We have identified a potent cysteine protease
inhibitor of the rodent parasite Plasmodium berghei, which
is expressed throughout the life cycle of the parasite. The
inhibitor appears to play a role in sporozoite invasion of
host cells and in parasite survival during liver stage
development by inhibiting host cell proteases involved
in programmed cell death.
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was obtained when reverse transcriptase had been omitted from
the RT-PCR (negative control).
Generation of antibodies
25 mg of each of the purified fusion proteins His-PbICP-C,
MBP-PbICP (full length) and MBP-PbICP-N in PBS buffer were
mixed with one volume Freund’s adjuvant complete (Sigma) and
intraperitoneally injected into BALB/c or NMRI mice. After two
weeks, the mice were boosted with the same amount of protein
mixed with Freund’s adjuvant incomplete (Sigma) followed by a
second boost two weeks later. Immunized mice were killed after
confirming the antibody response in preliminary experiments, and
blood was collected by cardiac puncture. Antisera were obtained
after centrifugation and diluted with one volume glycerol (Roth)
for long term storage at 220uC.
Rabbit antisera against His-PbICP-C, rabbit antisera against a
peptide within the PbICP-N sequence and the appropriate
preimmune sera were obtained from Eurogentec S.A.
In vitro infection of HepG2 cells
Human hepatoma cells (HepG2) were obtained from the
European cell culture collection. Cells were cultivated at 37uC
and 5% CO2 in EMEM (PAA) containing 10% fetal calf serum,
2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin
(all PAA Laboratories GmbH). For infection, 56104 cells were
seeded per coverslip in a 24-well plate. P. berghei (ANKA)
sporozoites were prepared from salivary glands of infected
Anopheles stephensi mosquitoes and incubated with HepG2 cells in
EMEM (PAA) containing 3% bovine serum albumin (Sigma),
2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin
(all PAA Laboratories GmbH) at 37uC and 5% CO2. After
2 hours, cells were washed and incubated in fresh culture medium
for the indicated times.
SDS-PAGE and Western blotting
Parasite proteins were separated on 12% to 14% SDS-PAGE
gels under reducing conditions and transferred to nitrocellulose
membranes. Membranes were probed with rabbit antisera
directed against His-PbICP-C or a peptide of PbICP-N, anti-
GFP mouse monoclonal antibodies (Roche) or rabbit antisera
(Molecular Probes) and mouse anti-tubulin monoclonal antibody
(Sigma). Horseradish peroxidase-conjugated anti-rabbit (Cell
Signalling) or anti-mouse IgG (Pierce or Rockland) and enhancing
chemiluminescence substrate detection kits (Pierce and Bio-Rad)
were used for detection.
Immunofluorescence microscopy
Sporozoite IFA. Sporozoites were isolated from salivary
glands of A. stephensi mosquitoes and incubated on glass
coverslips with or without HepG2 cells in EMEM (PAA)
containing 3% bovine serum albumin (Sigma), 2 mM L-
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (all
PAA Laboratories GmbH) at 37uC and 5% CO2. After 2 hours,
medium was carefully removed and sporozoites were fixed with
4% formaldehyde in PBS (20 min, room temperature),
permeabilized with ice-cold methanol (10 min) and incubated
with primary antisera (rabbit anti-His-PbICP-C, mouse anti-CSP,
mouse anti-TRAP) and subsequently with fluorescently labeled
secondary antibodies (Cy2-labeled antibodies, Dianova and
Alexa594-labeled antibodies, Molecular Probes). DNA was
visualized by staining with 10 mg/ml DAPI (Sigma). Labeled
cells were analyzed by widefield or confocal microscopy using the
Leica DM RB or Olympus FV1000.
Staining of unfixed sporozoites. Sporozoites expressing
cytosolic mCherry [51] were isolated from salivary glands of A.
stephensi mosquitoes and incubated for 40 minutes on ice in PBS
with a 1:100 dilution of rabbit antiserum directed against His-
PbICP-C, the appropriate preimmune serum or mouse antiserum
directed against CSP. Sporozoites were washed twice with cold PBS
and subsequently incubated with a 1:200 dilution of the Cy2-labeled
anti-rabbit or anti-mouse secondary antibody (Dianova) and
Hoechst 33258 (Molecular Probes) for 30 min on ice. Sporozoites
were washed twice, settled on coverslips with DAKO Fluorescent
Mounting Medium (DAKO) and immediately analyzed by
widefield fluorescence microscopy using the Leica DM RB.
IFA of infected HepG2 cells. HepG2 cells were infected as
described above. After the indicated time periods, cells were fixed
with 4% formaldehyde in PBS (20 min, room temperature),
permeabilized with ice-cold methanol (10 min) and incubated
with primary antibody (chicken anti-ExpI, mouse anti-CSP) and
subsequently with fluorescently labeled secondary antibodies (Cy2-
labeled antibodies, Dianova and Alexa594-labeled antibodies,
Molecular Probes). DNA was visualized by staining with 10 mg/
ml DAPI (Sigma). Labeled cells were analyzed by widefield or
confocal microscopy using the Leica DM RB or Olympus FV1000.
Immunoelectron microscopy
Midguts and salivary glands of P. berghei infected A. stephensi
mosquitoes were isolated, fixed in 2% paraformaldehyde and
0.025% glutaraldehyde and slowly embedded in LR WhiteTM
Resin (London Resin Company) after dehydration. Briefly,
ultrathin sections were incubated with rabbit antiserum directed
against His-PbICP-C and subsequently with gold (10 nm)-labeled
Protein A.
For double staining, ultrathin sections were first incubated with
anti-TRAP mouse antiserum and subsequently with gold (10 nm)-
labeled anti-mouse IgG and afterwards with rabbit antiserum
directed against His-PbICP-C and with gold (25 nm)-labeled
Protein A.
Sections were stained with 2% uranyl acetate and 1:10 diluted
Reynold’s lead citrate solution in 0.01 N NaOH. Sections were
analyzed using the FEI Tecnai TEM.
Transfection of P. berghei
DNA was amplified from cDNA of P. berghei ANKA wildtype
mixed blood stage parasites using the primer pair PbICPpL17-fw (59-
CTGGGATCCATGAAAAGTATAACTTTTTTCGTGTTTAAT-
39) / PbICPpL17-rev (59-CTGGGATCCTTGGACAGTCACGTATA-
TAATTTTAGTGTT-39).The resulting fragment was cloned into the
P. bergheiGFP transfection plasmid pL0017 (MR4) using the BamHI site
in front of the gfp gene. The plasmid was linearized for transfection
using the restriction sites of SacII and ApaI in the ssu integration site
sequence. Schizont-stage parasites were transfected with 2.5 and 7.5 mg
purified plasmid DNA as described by Janse et al. [52].
Analysis of the transgenic parasites during the liver
stage. To monitor parasite growth over the course of
development, parasite size was measured by the density slice
module of the OpenLab software version 5.0.2. Briefly, at different
time points after infection (24 hpi (hours post infection), 48 hpi, 63
hpi), transgenic parasites over-expressing PbICP-GFP and control
parasites were photographed. Images from each time point were
merged and OpenLab software version 5.0.2 was used to produce
a density slice of the image and to calculate the parasite areas.
An inside/outside assay to investigate infection efficiency was
performed as follows: 16105 HepG2 cells were seeded per
coverslip in a 24-well plate. The following day, transgenic
PbICP-GFP sporozoites and GFPcon sporozoites as control were
Plasmodium berghei Cysteine Protease Inhibitor
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prepared from salivary glands of infected A. stephensi mosquitoes
and counted in a Neubauer chamber. 26104 sporozoites per
sample were added to the HepG2 cells. After 1 h incubation at
37uC and 5% CO2, cells were fixed for 2 min with 2%
formaldehyde in PBS (no permeabilization) and incubated with
rabbit or mouse anti-CSP antiserum and subsequently with
fluorescently labeled secondary antibody (Alexa594-labeled anti-
bodies, Dianova). DNA was visualized by staining with 10 mg/ml
Figure 1. PbICP is a potent inhibitor of C1 cysteine proteases and the pbicp gene is constitutively transcribed. (A) Recombinant PbICP
inhibits papain activity. Recombinant PbICP was produced in E. coli as an MBP-tagged soluble protein and purified from the bacterial lysate by
amylose-bead affinity chromatography (insert, lane 1). The MBP tag was cleaved off by factor Xa digestion (insert, lane 2) and PbICP was purified
using a MonoQ column (insert, lane 3). Proteins were resolved by SDS-PAGE and stained with Coomassie Blue. Hydrolysis of the substrate Z-Phe-Arg-
pNA by papain was measured in the presence of 100 nM of the control protein MBP or 100 nM of MBP-PbICP, factor Xa-cleaved MBP-PbICP or PbICP
after tag cleavage and MonoQ purification. Protease activity in presence of 100 nM MBP was considered 100% and the percentage of residual
protease activity was calculated from that. MBP: maltose binding protein. (B) Constitutive transcription of the pbicp gene. RNA was isolated from P.
berghei-infected mouse blood, mosquito midgut and salivary glands and from infected HepG2 cells. The purified RNA was then used for a duplex RT-
PCR with specific primer pairs for the amplification of pbicp cDNA and the tubulin cDNA of P. berghei. In samples with odd numbers, cDNA was used
as a template. In samples with even numbers, reverse transcriptase was omitted from the cDNA preparation reaction to control for the presence of
genomic DNA.
doi:10.1371/journal.ppat.1000825.g001
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DAPI (Sigma). Sporozoites that have invaded cells are protected
against CSP staining and are visualized just by the GFP
fluorescence. In contrast, free GFP-positive sporozoites are stained
by the CSP antibodies. Free and intracellular sporozoites were
counted and their percentages were calculated.
Sporozoites neutralization assays
Pre-incubation in antisera. The neutralization assay was
mainly performed as described by Kumar et al. [53]. 16105
HepG2 cells were seeded per coverslip in a 24-well plate. The
following day, P. berghei (ANKA) sporozoites were prepared from
salivary glands of infected A. stephensi mosquitoes and counted in a
Neubauer chamber. For the inside/outside assay, red fluorescent
sporozoites expressing cytosolic mCherry protein were used [51].
26104 sporozoites per sample were incubated in 30 ml of the anti-
His-PbICP-C rabbit antiserum, the appropriate preimmune serum
or anti-CSP rabbit antiserum for 40 min on ice. Afterwards, pre-
warmed medium containing 3% bovine serum albumin (Sigma),
2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml
streptomycin (all PAA Laboratories GmbH) was added to the
samples. The sporozoite suspension was then added to HepG2
cells. Analysis of the neutralization assays was performed by
different established methods (transmigration assay, inside/outside
assay for invading sporozoites or counting of infected hepatocytes
30 hpi (detailed description see below)).
Transmigration assay. The suspension of sporozoites was
mixed with 1 mg/ml dextran-fluorescein (10,000 MW, Molecular
Probes) prior being added to the HepG2 cells. 1 h after incubation
at 37uC and 5% CO2, cells were washed three times in PBS, fixed
with 4% formaldehyde in PBS (20 min, room temperature) and
permeabilized with ice-cold methanol (10 minutes). To visualize
the sporozoites, CSP-staining was performed (mouse anti-CSP,
Alexa594-labeled anti-mouse antibody, Molecular Probes). DNA
was stained with 10 mg/ml DAPI (Sigma). The number of
transmigrated cells was determined by calculating the percentage
of dextran-fluorescein-positive cells as a percentage of all cells.
HepG2 cells without sporozoites served as control (basal rate of
wounded cells).
Inside/outside assay. 1 h after incubation at 37uC and 5%
CO2, cells were fixed for 2 min with 2% formaldehyde in PBS (no
permeabilization) and incubated with rabbit or mouse anti-CSP
antiserum and subsequently with fluorescently labeled secondary
antibody (Cy2-labeled antibodies, Dianova). DNA was visualized
by staining with 10 mg/ml DAPI (Sigma). Sporozoites that have
invaded cells are protected against the CSP-staining and were
visualized only by the mCherry expression. Free mCherry
sporozoites were additionally stained by the CSP antibodies.
Sporozoites were counted and the percentage of free and
intracellular sporozoites was calculated.
Counting of infected hepatocytes in the schizont
stage. After 2 h incubation at 37uC and 5% CO2, cells were
washed and fresh culture medium was added. 24 to 30 hours after
infection, cells were used for IFA and the numbers of infected
HepG2 cells per coverslip were determined. More than 200
infected cells were counted in the preimmune controls and set to
100% for each of the three independent experiments.
Transfection of HepG2 cells and cell death assays
DNA was amplified from cDNA of P. berghei ANKA wildtype
mixed blood stage parasites using the primer pair PbICP-CpEGFP-
fw (59-TTGAATTCGGAGATGAAAAATGTGGTAAATCA-39)
/ PbICP-C pEGFP -rev (59-TTGGATCCTTATTGGACAGTCA-
CGTATATAAT-39).
The resulting fragment was cloned into the pEGFP-C2 vector
(Clontech) to generate a GFP-PbICP-C-fusion protein. The vector
pEGFP-C2 alone was used as the GFP control.
HepG2 cells were grown in single wells of a 6-well plate at 70–
80% confluence and transfected using MATra technology (IBA) as
recommended by the manufacturer. Briefly, cells were washed
with PBS and reduced-serum OptiMEM media (PAA) was added.
5 mg of the appropriate plasmid DNA was pre-incubated with 5 ml
of MATra-A reagent in OptiMEM media for 20 min at room
temperature and then added to the cells. The cells were incubated
with the DNA-MATra complex on a universal magnetic plate
(IBA) for 30 min at 37uC and 5% CO2.
The next day transfected cells were treated with 70 nM tBHP
(tert-butylhydroperoxid, Sigma-Aldrich) for 4 hours or 1 mM
CAM (camptothecin, Sigma-Aldrich) for 48 hours. Cells were
washed with PBS and stained with 25 nM TMRE (tetramethylr-
hodaminethylesterperchlorat, Molecular Probes) and 16 mM
Hoechst 33258 (Molecular Probes) at 37uC and 5% CO2 for
30 min. Live imaging was performed using an inverse microscope
(Axiovert 25, Zeiss) and the Openlab 5 software (Improvision).
Results
Sequence peculiarities, expression and biochemical
characterization of PbICP
To investigate the regulation of cysteine protease activity by
exoerythrocytic P. berghei parasites, we analyzed the structural and
biochemical properties of the P. berghei homolog of falstatin/PfICP,
PbICP. It belongs to the chagasin-like inhibitor family (MEROPS-
family I42, termed ICP for inhibitor of cysteine proteases). ICPs
are so far the only cysteine protease inhibitors known to exist in
protozoan parasites. Typically, ICPs are small proteins with a low
sequence similarity to each other but a characteristic b-sheet-rich
secondary structure similar to immunoglobulins [54,55,56,57].
Three loops (L2, L4, L6) form a wedge-like structure that extends
into the active site cleft of C1 family cysteine proteases (papain
superfamily). The ICPs of the apicomplexan protozoan parasites
Plasmodium and Toxoplasma gondii are unusual chagasin family
members [40,43] in that they differ more than other members in
sequence and even in length of the wedge-forming loops (Figure
S1, S2A). Moreover, the Plasmodium ICPs contain an additional N-
terminal extension region resulting in an overall molecular weight
of about 40 kDa. PbICP shares approximately 40% amino acid
sequence identity with falstatin/PfICP but only about 21% with
chagasin of Trypanosoma cruzi, the first described member of the
Table 1. Recombinant PbICP is a potent inhibitor of cysteine
proteases but not of cathepsin B.
papain cathepsin L falcipain-2 cathepsin B
1 mM MBP 100 100 100 100
1 mM MBP-PbICP 361 060,2 060,1 10062
100 nM MBP 100 100 100 100
100 nM MBP-PbICP 962 161 n.d. 10260,1
100 nM PbICP 1262 16613 2465 10362
Substrate hydrolysis was measured in the presence of the control protein MBP
(1 mM or 100 nM) or in the presence of MBP-PbICP (1 mM or 100 nM) or PbICP
(100 nM). Experiments were performed in triplicate. Protease activity in the
presence of 1 mM and 100 nM MBP, respectively was considered as 100% and
the percentage of residual protease activity in the presence of the inhibitor was
calculated. n.d. not done.
doi:10.1371/journal.ppat.1000825.t001
Plasmodium berghei Cysteine Protease Inhibitor
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inhibitor family. Secondary-structure prediction programs propose
that PbICP contains the characteristic b-sheet-rich structure with
two additional b-strands (b59and b50) between the elongated L3
and L4 (Figure S2B).
The pbicp gene consists of two exons (exon 1: 63 bp; exon 2:
999 bp) and an intron of 519 bp. The first exon codes for a classical
signal peptide while the second exon codes for the mature protein.
To confirm that PbICP acts as a cysteine protease inhibitor, we
produced recombinant PbICP as an MBP (maltose binding protein)
fusion protein in E. coli, purified the protein by affinity chromatog-
raphy and removed the MBP tag by factor Xa digestion and
subsequent ion exchange chromatography (Figure 1A). PAGE
analysis of the purified proteins revealed MBP-PbICP to be 97 kDa
in size (55 kDa without tag), which is considerably larger than the
size calculated from the amino acid sequence (82 kDa and 40 kDa
with and without tag, respectively). We tested the purified MBP-
tagged and untagged PbICP in protease assays using cysteine
proteases of the C1 family that are the known targets of chagasin-
like inhibitors. 1 mM and 100 nM of both tagged and untagged
PbICP strongly inhibited papain, the P. falciparum cysteine protease
falcipain-2 and human cathepsin-L (Figure 1A, Table 1). Like
falstatin [40], PbICP did not inhibit cathepsin B. This is in contrast
to chagasin, the ICP of L. mexicana (LmICP) and the ICP of T. brucei
(TbICP) [37,58], which are all reported to inhibit cathepsin B, to
various extents. We compared the ICP1 of E. histolytica (EhICP1)
and PbICP in their capacity to inhibit cathepsin B and found that
EhICP1 blocked this protease but PbICP did not (data not shown).
PbICP is expressed throughout the life cycle of P. berghei
Our next aim was to analyze expression of PbICP in various life
cycle stages of P. berghei. First, we investigated pbicp mRNA
expression. RNA was isolated from P. berghei insect stages (oocyst
and salivary gland sporozoites), red blood cells from infected
NMRI mice and infected hepatoma cells. Duplex RT-PCR assays
suggested that pbicp, like tubulin, is constitutively transcribed
throughout the life cycle stages analyzed (Figure 1B).
Figure 2. PbICP is secreted by salivary gland sporozoites. (A) Widefield IFA of P. berghei sporozoites that have been allowed to glide on glass
coverslips. Sporozoites were fixed after 1 h and subsequently stained with anti-CSP antiserum (mouse, red) and polyclonal antiserum against PbICP-C
(rabbit, green). DNA was stained with DAPI (blue). Like the shedded surface protein CSP, PbICP was detected in a patchy pattern in the trails of the
circling sporozoites. (B) IEM confirms PbICP localization in vesicles of a midgut sporozoite. P. berghei infected A. stephensi midguts were fixed 20 days
after infection and prepared for IEM. Ultrathin sections were stained with polyclonal antiserum directed against PbICP-C (rabbit) and subsequently
with gold-labeled Protein A (10 nm gold particles). The sections were contrasted with uranyl acetate and lead citrate.
doi:10.1371/journal.ppat.1000825.g002
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To determine PbICP expression in the exoerythrocytic parasite
stages at the protein level, we produced specific antisera against
recombinant PbICP in rabbits as well as mice and used them in
indirect immunofluorescence analysis (IFA), immunoelectron
microscopy (IEM) and western blot analysis. An overview is
provided of the different antisera generated against the full-length
PbICP, PbICP domains (PbICP-N and PbICP-C) and PbICP
peptides (Figure S3), as well as of representative experiments
demonstrating the specificity of the antisera (Figure S4 and S5).
In agreement with the transcription profile of the pbicp gene, the
PbICP protein could be detected in all exoerythrocytic parasite
stages (Figures 2–4). PbICP expression and localization in
sporozoites, liver schizonts and detached cells/merosomes will
now be explained in detail.
Sporozoites secrete PbICP
Extracellular gliding sporozoites were fixed and stained with an
antiserum directed against the C-terminal domain of PbICP,
revealing that sporozoites secrete the inhibitor (Figure 2A). PbICP
was detected in distinct areas of the parasite and in protein trails
left behind by gliding sporozoites. These trails also contain the
major sporozoite surface protein CSP (circumsporozoite protein)
that is shed during gliding motility., In permeabilized sporozoites,
PbICP staining showed a patchy pattern suggesting a localization
in secretory vesicles, which was confirmed by IEM (Figure 2B).
TRAP (Thrombospondin-related anonymous protein) is a micro-
nemal protein and, in the presence of host hepatocytes,
accumulates at the apical end of the sporozoite [59,60]. IFA
revealed a similar staining pattern for PbICP, suggesting that an
exocytosis-like secretion of the inhibitor occurs as for TRAP
(Figure 3A). In addition, staining of unfixed sporozoites with an
anti-PbICP-C antiserum confirmed the localization at the apical
pole of the sporozoites (Figure S5).
To investigate whether the PbICP-containing vesicles are
micronemes, we performed double staining IEM analysis of
sporozoites using TRAP as a micronemal marker protein
(Figure 3B). In agreement with the confocal IFA, the IEM analysis
showed a partial colocalization of TRAP and PbICP in secretory
vesicles. Thus, we conclude that at least a portion of PbICP is
translocated to the micronemes.
Following invasion of hepatocytes, intracellular parasites
continue secreting PbICP, which was detected in the host cell
cytoplasm (Figure 4A,B, Figure S6, Figure S7). To ensure we
were monitoring invading and not transmigrating parasites, we
fixed cells at 4 hpi (hours post infection), when sporozoites are
no longer motile. At this stage, some sporozoites had already
Figure 3. PbICP partially colocalizes with TRAP at the apical pole and in vesicles of sporozoites. (A) Confocal IFA of an extracellular P.
berghei sporozoite in the presence of HepG2 cells. HepG2 cells were co-cultivated for 1 h with sporozoites, fixed and stained with an anti-TRAP
antiserum (mouse, green) and a polyclonal antiserum against PbICP-C (rabbit, red). DNA was stained with DAPI (blue). (B) Double-stained IEM of a
salivary gland sporozoite shows partial co-localization of TRAP and PbICP in vesicles (marked with asterisk). P. berghei-infected A. stephensi salivary
glands were fixed 25 days after infection and prepared for IEM. Ultrathin sections were stained with PbICP-C (rabbit, 25 nm gold particles) and anti-
TRAP (mouse, 10 nm gold particles). The sections were contrasted with uranyl acetate and lead citrate.
doi:10.1371/journal.ppat.1000825.g003
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begun transformation into early trophozoites (Figure S6A). To
confirm export of PbICP into the host cytoplasm, we compared
the localization of PbICP with that of CSP, a molecule known
to be secreted by young trophozoites. Although we did
not detect co-localization of these proteins, the distribution
of CSP and PbICP in the infected hepatocyte was similar
for the majority of parasites, indicating PbICP secretion
(Figure S6B).
Figure 4. PbICP is expressed throughout the liver stage and localizes to different microenvironments. Wide-field IFA of HepG2 cells
infected with P. berghei-expressing mCherry in the cytoplasm (A) or wildtype P. berghei (B-F) at different time points after infection (hpi, hours post
infection). Infected cells were fixed, incubated with anti-CSP antiserum (mouse, red) (B) or with anti-ExpI antiserum (chicken, red) (C-F) and antiserum
against PbICP-C (rabbit, green) (A-F). DNA was stained with DAPI (blue).
doi:10.1371/journal.ppat.1000825.g004
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Figure 5. PbICP is posttranslationally processed in the blood stage and exoerythrocytic stages. (A) Domain-specific western blot analysis
of protein extracts prepared from P. berghei salivary gland sporozoites and blood stage schizonts. Protein extracts of blood stage schizonts (two
independent samples: one in lane 2 and a second one in lane 3+4) and sporozoites were separated by SDS-PAGE and blotted on nitrocellulose filters.
Filters were then probed with antisera against the chagasin-like domain of PbICP (anti-PbICP-C, rabbit, lane 1–3) or the N-terminal domain (anti-
PbICP-N, lane 4). Anti-PbICP-C antiserum detected the full-length inhibitor (55 kDa) as well as the processed form after cleavage of the N-terminal
extension domain (23 kDa), whereas anti-PbICP-N antiserum detected only the full-length protein of 55 kDa. (B) IFA of a P. berghei-infected HepG2
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In later liver stages, PbICP is translocated into the
parasitophorous vacuole and is released into the
hepatocyte cytoplasm upon merozoite formation
The PVM of early schizont stages can be stained with an
antiserum against the PVM-marker protein Exp1 of P. berghei.
PbICP co-localized partly with Exp1 but was additionally clearly
seen outside of the ring-shaped Exp1 staining, strongly suggesting
that the inhibitor is in contact with the host cell cytoplasm
(Figure 4C). In later schizont and cytomere stages, PbICP
localized mainly to the PV (Figure 4D, E, Figure S4B, Figure
S8, Figure S9), but was also found in the parasite cytosol. For these
stages we could not detect PbICP in the host cytoplasm. However,
PbICP was frequently found in close proximity to Exp1-positive
structures that appear to bud off or be released from the PVM
(Figure 4D, Figure S4B, Figure S8 and Figure S9).
After completion of daughter parasite development, the PVM
starts to disintegrate and this clearly correlates with marked PbICP
release into the hepatocyte cytoplasm (Figure 4F, Figure S10)
suggesting that PbICP could have an important function in the
regulation of host cell proteases and the regulated host cell death
induced at this time. Upon PVM rupture and PbICP release,
merozoites are liberated into the host cell cytoplasm and thus are
in direct contact with PbICP, which might protect them from
proteolytic damage.
PbICP is posttranslationally processed
Western blot analysis using anti-PbICP antisera revealed that
PbICP is subject to posttranslational processing during the sporozoite
stage and frequently also during the blood stage of the parasite
(Figure 5A). Antisera directed against the C-terminal chagasin-like
domain of PbICP not only detected a protein that corresponds to the
full-length PbICP but also a 23 kDa protein that corresponds to the
chagasin-like C-terminal domain of PbICP. An antiserum directed
against the N-terminal extension region of PbICP only detected the
full-length inhibitor, indicating that the N-terminal region is rapidly
degraded after the proteolytic cleavage. While in sporozoites
processing of PbICP was always detected, the situation was less clear
for blood stage parasites. In protein extracts of this stage we
sometimes exclusively found unprocessed PbICP (Figure 5A),
similarly to what has been published for falstatin/PfICP of P.
falciparum [40] but in other preperations processed PbICP was also
detected. As both non-processing and partial processing were seen in
the schizont stage, the degree of processing does not seem to relate to
the developmental stage of the parasite. Since the focus of this study
was on exoerythrocytic parasites, we did not follow up this interesting
phenomenon in detail. Blood stage protein extracts were nevertheless
used as an easily accessible source of protein for western blotting to
address questions unrelated to processing. Importantly, the size of the
full-length inhibitor detected by western blotting corresponds to the
cell 48 hpi (widefield deconvolution). Infected cells were fixed and stained with anti-PbICP-N antiserum (mouse, red) and antiserum against PbICP-C
(rabbit, green). DNA was stained with DAPI (blue). The images were deconvoluted to remove out-of-focus signals. (C) Schematic illustration of the
transfection plasmid pL0017-pbicp-gfp for constitutive strong expression of PbICP. The pbicp-gfpm3 coding region (ss, signal sequence of pbicp) is
under the control of the strong constitutive pbeef1aa promotor. The vector confers ampicillin resistance (amp+) in E. coli and pyrimethamine
resistance (pyr+) in transfected P. berghei parasites. Following transfection, P. berghei parasites constitutively express the fusion protein. The expected
in gel sizes of the GFP-tagged full-length PbICP and the GFP-tagged processed form of the inhibitor were calculated and are presented. (D) Anti-GFP
western blot analysis of GFP-PbICP-expressing P. berghei blood stage extracts, sporozoite total lysates, infected HepG2 cell total lysates (60 hours after
infection) and detached infected HepG2 cells/merosomes. Uninfected HepG2 cells served as a specificity control and reprobing with anti-tubulin
antiserum served as a loading control for protein extracts of infected and uninfected HepG2 cells. The anti-GFP antiserum detected proteins that
correspond to the size of the full-length GFP-tagged inhibitor (81 kDa) as well as the processed form after cleavage of the N-terminal extension
domain (49 kDa).
doi:10.1371/journal.ppat.1000825.g005
Figure 6. The C-terminal domain of PbICP is necessary and sufficient for the inhibitor function. (A) Purification of recombinant PbICP,
PbICP-C and -N. Like the full-length protein, recombinant PbICP-C and -N were expressed in E. coli as MBP-tagged soluble proteins and purified from
the bacterial total lysate by amylose-bead affinity chromatography (lane 1, 2, 3). The proteins were resolved by SDS-PAGE and stained with
Coomassie Blue. (B) Recombinant PbICP-C inhibits the cysteine protease cathepsin L to a similar extent as full-length PbICP, whereas PbICP-N does
not block cathepsin L activity. Hydrolysis of the substrate Z-FR-pNA by cathepsin L was measured in the presence of 1 mM MBP-PbICP-N, MBP-PbICP
or MBP-PbICP-C or the control protein MBP.
doi:10.1371/journal.ppat.1000825.g006
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size of recombinant PbICP, suggesting that parasite-derived PbICP is
not posttranslationally modified other than by processing (data not
shown). To analyze processing of PbICP during liver stage
development by western blotting, we generated a P. berghei strain
expressing a PbICP-GFP fusion protein under the control of a strong
constitutive promotor (eef1aa) (Figure 5C). PbICP overexpression was
necessary because infection rates of HepG2 cells are in general very
low (2–10%) and do not allow detection of endogenous proteins by
western blotting. Using this PbICP-overexpressing transgenic strain
for HepG2 cell infection, it was then possible to demonstrate PbICP
processing before and after the detachment of infected hepatocytes at
the end of the liver stage (Figure 5D). Overexpression of the PbICP-
GFP fusion protein had no negative effects on parasite development
suggesting that the presence of the fusion protein is not toxic for
exoerythrocytic parasites (Figure S11A-E). Interestingly, transgenic
parasites constitutively expressing PbICP-GFP showed a slightly but
significantly increased level of HepG2 cell invasion compared to
wildtype parasites (Figure S12). To prove PbICP processing also
occurs in wildtype parasites, we employed immunofluorescence
analysis using antisera against both PbICP-C and PbICP-N. We
reasoned that co-localization of these domains would indicate
unprocessed PbICP whereas staining exclusively with the PbICP-C
antiserum would indicate PbICP processing. The result of the
immunofluorescence analysis confirmed a proteolytic cleavage of
endogenous PbICP during the schizont stage of the parasite
(Figure 5B).
The C-terminal domain is necessary and sufficient for the
inhibitory function of PbICP
We then investigated whether the C-terminal domain of PbICP
on its own has inhibitory potential. PbICP-C, the region
homologous to chagasin, was expressed as an MBP fusion protein
(Figure 6A) and used in protease assays (Figure 6B, Table 2). Full-
length MBP-PbICP served as a positive control, MBP without any
fusion as a negative control. Additionally, PbICP-C was expressed
and purified without a tag and included in the analysis. Both
MBP-PbICP-C and PbICP-C blocked papain, cathepsin L and
falcipain-2 activity to the same extent as full-length MBP-PbICP,
whereas the tagged N-terminal domain (MBP-PbICP-N) did not
show any inhibitory effect on protease activity (Figure 6B, Table 2).
None of the recombinant proteins blocked the activity of cathepsin
B. Since the full-length inhibitor and PbICP-C did not differ in
inhibitory strength and specificity for the analyzed proteases, the
N-terminal domain does not appear to have a modulatory effect
on the inhibitor function at least in a non-cellular environment.
PbICP is involved in sporozoite invasion of hepatocytes
Since PbICP is secreted by sporozoites, we tested whether the
protein plays a role during sporozoite transmigration through cells
and invasion of HepG2 cells in vitro (Figure 7). Sporozoites were
pre-incubated in anti-PbICP antiserum and then used for the
different assays. Interestingly, the number of transmigrated cells
was higher for sporozoites pre-incubated with anti-PbICP
antiserum compared to sporozoites pre-incubated with anti-CSP
antiserum or preimmune serum (Figure 7A). However, since this
effect was not significant, we did not follow up this observation.
The most important conclusion from the transmigration assay was
that neutralization of PbICP does not interfere with the traversal
capability of sporozoites. Following transmigration, sporozoites
finally invade cells and reside in a PV. To investigate the effect of
PbICP blockage on the invasion process, we combined the
invasion assay with an inside/outside assay that allowed us to
distinguish between extracellular and intracelluar parasites [5]
(Figure 7B). Preincubation of sporozoites with antiserum against
PbICP-C significantly reduced the level of HepG2 cell infection by
P. berghei sporozoites by about 40% (from 37.6% to 22.8% in
Figure 7B). The inhibitory effect on sporozoite invasion by
blocking PbICP activity fits well with the observation that
transgenic P. berghei parasites over-expressing a GFP-PbICP fusion
protein exhibited an improved invasion rate (Figure S12).
To exclude an effect of PbICP neutralization during invasion on
parasite development, we additionally analyzed infected cells 30
hpi. The number of parasites that developed to the schizont stage
(see image in Figure 7C) was significantly reduced by 46% or 26%
when sporozoites were pre-treated with 1:5 or 1:10 dilutions,
respectively, of the anti-PbICP antiserum in comparison to the
pre-immune control serum (Figure 7C). The reduction of
developing parasites by 46% after pretreatment of sporozoites
with 1:5 dilution of the serum reflects the result of the inside/
outside assay, where the number of invaded sporozoites was
reduced by almost the same extent (40%). In conclusion, the
blocking capacity of the antiserum is restricted to sporozoite
neutralization and does not affect later parasite development. As
expected, preincubation of sporozoites in 1:10 diluted anti-CSP
antiserum resulted in a strong (75%) reduction of the number of
infected HepG2 cells 30 hpi.
PbICP blocks host cell death
Since PbICP is released into the host cell cytoplasm both by
sporozoites and at the end of the liver stage, the question is raised
whether host cell cysteine proteases are target molecules of the
parasite inhibitor. Cysteine proteases such as caspases, calpains
and cathepsins are often key enzymes in programmed cell death
execution. Interestingly, when host hepatocytes undergo their
unusual cell death upon merozoite release from the PVM, caspases
are not activated and other classical signs of programmed host cell
death are also absent, including DNA fragmentation and
phosphatidylserine switching to the outer plasma membrane
leaflet [16]. We hypothesized that PbICP may modulate activation
of programmed host cell death by inhibiting host cell cysteine
proteases. HepG2 cells were transfected with a plasmid coding for
N-terminally GFP-tagged PbICP-C or with a control vector and
subsequently cell death was induced by treatment with tert-butyl
hydroperoxide (tBHP). Viability of cells was analyzed by staining
with TMRE, a dye which only labels mitochondria with intact
membrane potentials and thus indicates viable cells. Additionally,
cells were stained with the DNA dye Hoechst 33258 to visualize
Table 2. The C-terminal domain but not the N-terminal
domain of PbICP is a potent inhibitor of cysteine proteases
except cathepsin B.
papain cathepsin L falcipain-2 cathepsin B
1 mM MBP 100 100 100 100
1 mM MBP-PbICP-N 8961 10164 12862 9367
1 mM MBP-PbICP-C 562 160,2 060,1 10061
100 nM MBP 100 100 100 100
100 nM PbICP-C 1262 21610 1860,1 10562
Substrate hydrolysis was measured in the presence of the control protein MBP
(1 mM or 100 nM), in the presence of MBP-PbICP-C (1 mM), in the presence of
MBP-PbICP-N (1 mM) or in the presence of PbICP-C (100 nM). Protease activity in
the presence of 1 mM and 100 nM MBP, respectively was considered as 100%
and the percentage of residual protease activity in the presence of the inhibitor
was calculated.
doi:10.1371/journal.ppat.1000825.t002
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Figure 7. Antibody-mediated neutralization of PbICP reduces infectivity of sporozoites in vitro but does not inhibit cell traversal of
sporozoites. (A) Transmigration assay: P. berghei sporozoites were pre-incubated with medium (no serum) preimmune serum (1:5), anti-PbICP-C
antiserum (1:5) or anti-CSP-antiserum (1:5) and subsequently added to HepG2 cells in the presence of 1 mM dextran-fluorescein for 1 h to stain
wounded cells. Non-infected HepG2 cells (n.i.) cultivated in the presence of 1 mM dextran-fluorescein for 1 h served as a negative control for cell
wounding. After this incubation period cells were washed, fixed and the DNA was stained with DAPI to allow visualization of both intact and
wounded cells. The total cell number compared to dextran-fluorescein positive cells was determined using an immunofluorescence microscope and
the percentage of dextran-fluorescein positive cells was calculated. Presented are the means and standard deviations of three independent
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chromatin condensation of dying cells (Figure 8A). In contrast to
the control cells expressing GFP, of which only 26% were alive,
after 7 h of tBHP treatment, 80% of the GFP-PbICP-C-
expressing HepG2 cells were still viable (Figure 8B). Similar
results were achieved when infected cells were treated with the
apoptosis-inducing agent camptothecin (CAM) for 48 h (Figure
S14). From these experiments we conclude that PbICP indeed has
the capacity to suppress or interfere with the cell death machinery
of hepatocytes by blocking host cell cysteine proteases involved in
cell death execution. The possible function of PbICP during the
entire exoerythrocytic development in vitro is summarized in
Figure 9.
Discussion
Parasite and host cell cysteine proteases play an important role
during the entire life cycle of the Plasmodium parasite. Cysteine
protease activity is essential for sporozoite egress from oocysts in
the mosquito [19], sporozoite invasion of hepatocytes in the
vertebrate host [20,21], liver stage development and liberation of
exo-erythrocytic merozoites from hepatocytes [16] as well as for
invasion, nutrition and egress in the blood stage [18]. All these
protease activities must be strictly regulated to prevent undesired
and harmful proteolytic activity. In addition to controlling its own
proteases, the malaria parasite is exposed to proteases of the host,
such as those from inflammatory cells that are secreted to
eliminate pathogens and perhaps also intra-hepatocyte proteases
encountered by the parasite during liver stage development.
In this study, we report the identification of the potent cysteine
protease inhibitor PbICP, the falstatin/PfICP homolog of the
rodent malaria parasite P. berghei. Like falstatin/PfICP [40], PbICP
is an unusual member of the chagasin inhibitor family with
obvious structural peculiarities due to (1) the long N-terminal
extension domain, (2) sequence insertions in the chagasin-like C-
terminal domain and (3) amino acid exchanges in conserved
motifs. The inhibitor is expressed in all analyzed stages of P. berghei
(blood stage, sporozoites, liver stages) and according to its different
localizations it can potentially control parasite as well as host cell-
derived proteases.
We provide several lines of evidence that PbICP is secreted by
P. berghei sporozoites to support host cell invasion. First, the
inhibitor was detected in typical CSP-positive sporozoite trails [61]
by IFA of fixed parasites using a specific anti-PbICP antiserum.
Second, IEM analysis revealed the presence of PbICP in vesicles
within sporozoites. Third, some of the PbICP-positive vesicles
appear to be secretory micronemes since they were found by IEM
analysis to be positive for both PbICP and the micronemal marker
protein TRAP [62,63,64,65]. Fourth, IFA of live sporozoites
revealed PbICP to be in a characteristic protein cap formation at
the apical pole, as has been seen for the TRAP protein after
regulated exocytosis [59,60]. Finally, pre-incubation of viable
sporozoites in anti-PbICP immune serum significantly reduced the
number of sporozoites invading HepG2 cells.
PbICP does not contain an obvious micronemal targeting motif
but since these motifs are rather heterogenous (as in TRAP and
EBL proteins [62,66]), empirical studies will be necessary to
determine the motif that targets PbICP to the micronemes of the
sporozoite. As a soluble protein, PbICP may even lack such a motif
but might be sorted by formation of complexes with escorter
proteins, as is known for soluble micronemal MIC proteins of
Toxoplasma [67].
Our results are supported by a previous study on the Plasmodium
gallinaceum ICP [68], which was termed PgSES for P. gallineceum
sporozoite and erythrocyte stage protein. In this study, PgSES/
PgICP was not identified as a cysteine protease inhibitor but was
characterized as a secreted sporozoite protein with a characteristic
localization pattern. Similar to what we describe for P. berghei
sporozoites, LaCrue et al. found a patchy intracellular distribution
of PgSES/PgICP in the sporozoite and an extracellular staining
pattern distinct from CSP, mainly on salivary gland sporozoites
[68].
The target protease of sporozoite-secreted PbICP remains to be
identified, but interestingly it was reported that a cysteine
protease-dependent CSP cleavage is essential for the invasion
process [20,21]. The responsible protease has not yet been
identified but is of parasite origin and becomes activated upon
interaction of the parasite with highly sulfated heparan sulfate
proteoglycans (HSPGs) on hepatocytes. Since PbICP is capable of
regulating cysteine proteases, and since both molecules act outside
of the sporozoite, it is possible that PbICP controls this parasite
protease in a timely and well-orchestrated manner to avoid
premature CSP proteolysis.
When sporozoites were pre-incubated with anti-PbICP antise-
rum, we not only observed a reduced invasion rate but also a
tendency of enhanced transmigration. It has been suggested earlier
that sporozoites which are blocked from invasion persist in the
migratory state [21] and it might well be that we provoked a
similar effect by neutralizing the protease inhibitor.
In agreement with our findings that PbICP contributes to
hepatocyte infection by P. berghei sporozoites, many of the so far
characterized chagasin-like inhibitors of other intracellular proto-
zoan parasites also play an important role during host cell invasion
processes. Falstatin/PfICP is released together with P. falciparum
merozoites upon rupture of infected red blood cells. Treatment
with antibodies directed against falstatin/PfICP decreased the
subsequent invasion of erythrocytes in a dose-dependent manner,
suggesting a role in limiting unwanted proteolysis during
erythrocyte invasion [40]. The ICPs of Trypanosoma are predicted
to regulate endogenous proteases of the parasite [45,46]. Amongst
other effects on differentiation and protein turnover, overexpres-
experiments. The image presented shows a number of cells, whose nuclei are stained with DAPI. Transmigrated cells are additionally stained with
dextran-fluorescein (green). (B) Invasion assay: P. berghei sporozoites expressing mCherry were pre-incubated with preimmune serum (1:5), anti-
PbICP-C antiserum (1:5) or anti-CSP-antiserum (1:5) and subsequently added to HepG2 cells. After 1 h, cells were fixed but not permeabilized and
stained with an anti-CSP antiserum (inside/outside assay). All sporozoites can be detected by their mCherry expression but only extracellular
sporozoites are additionally stained by the anti-CSP antiserum. DNA was stained with DAPI (blue). Free and intracellular sporozoites were counted
and the percentage was calculated. Presented are the means and standard deviations of three independent experiments. Typical examples of
intracellular and extracellular parasites are presented in the image next to the graph. mCherry expression can be seen in all sporozoites but additional
CSP staining (green) is visible only in extracellualr parasites. (C) Parasite development following PbICP neutralization of sporozoites: HepG2 cell
infection was performed as described in (B). Serum dilutions (1:5 to 1:50) used to pre-incubate sporozoites are indicated. Infected cells were fixed 30
hpi and stained with anti-Exp1 antiserum (chicken, green) and anti-PbICP-C antiserum (rabbit, red) (image shows a typical example of a infected cell
30 hpi stained as described). Infected cells in the individual wells were counted and the percentage of infected cells after treatment was calculated
from three independent experiments. The number of infected cells in wells infected with sporozoites that had been exposed to a 1:10 dilution of the
preimmune serum, was considered as 100%. As in the CSP-control, pre-incubation with anti-PbICP-antiserum significantly reduced the infectivity of
sporozoites.
doi:10.1371/journal.ppat.1000825.g007
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sion of chagasin in T. cruzi resulted in a reduced infection rate in
vitro, while T. brucei ICP null mutants reached higher parasitemia
levels in mice [45,46]. Endogenous L. mexicana ICP had no impact
on the infectivity of the parasites in vitro. However, when LmICP
null mutants and overexpressors were analysed in vivo in the mouse
model system, both showed a reduced virulence and infectivity
[38]. It is suggested therefore, that LmICP controls host-derived
rather than parasite-derived proteases.
Upon sporozoite invasion of hepatocytes and transformation
into trophozoites, PbICP is still secreted by the parasite, entering
the PV and apparently reaching the host cell cytoplasm. Since a
PEXEL export motif is absent in PbICP, it is so far unknown how
the inhibitor crosses the PVM. It has been shown previously that
P. berghei infection protects host cells from apoptosis [14,15] and
PbICP translocated to the host cell cytoplasm might be involved in
the inhibition of caspases, which are cysteine proteases involved in
programmed cell death execution. Indeed, we provide the first
evidence that PbICP expression in the host cell cytoplasm is
sufficient to inhibit parasite-independent host cell death. Interest-
ingly, Pandey et al. have shown that falstatin/PfICP efficiently
blocks proteolytic activity of caspases in nano- to micromolar
concentrations [40]. It remains to be shown how PbICP could act
on enzymes as different as cathepsin-L-like proteases and caspases.
For C1 family members such as cathepsins, it is known that ICPs
bind to the active site cleft between the R and the L domain, but
caspases do not contain such a cleft [69]. A possible explanation is
that Plasmodium ICPs act similarly to members of the serpin family
due to the sequence insertions, which lead to elongated loops.
Figure 8. PbICP-C expression protects HepG2 cells against host cell death. (A) HepG2 cells were transiently transfected with plasmids
leading to either cytosolic expression of GFP-tagged PbICP-C or GFP as a control. The transfection efficiency of HepG2 cells with the control plasmid
and the GFP-PbICP-C plasmid (absolute numbers of GFP-positive cells/cover) were similar. Host cell death was induced by tBHP treatment for 4 h and
analyzed by live imaging using TMRE staining of intact mitochondria (red). DNA condensation was visualized by Hoechst 33258 staining (blue). Dying
cells exhibited condensed chromatin in the nucleus and a loss of the mitochondrial membrane potential. (B) Fluorescent cells were counted and the
percentage of dead and viable cells was calculated. Presented are the means and standard deviations of three independent experiments. Cells
expressing GFP-PbICP-C showed a significantly better survival following tBHP treatment in comparison to GFP-expressing cells.
doi:10.1371/journal.ppat.1000825.g008
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Serpins inhibit serine and cysteine proteases by using a flexible
loop (reactive site loop) as a bait to trap structurally different
proteases [70]. If Plasmodium ICPs indeed function similarly to
serpins, this would explain why falstatin/PfICP is an efficient
inhibitor of structurally different proteases.
At the end of the liver stage, the situation changes completely and an
ordered parasite-mediated cell death is induced. This form of cell death
clearly differs from apoptosis since caspases are not involved, there is no
switch in phosphatidylserine residues to the outer leaflet of the host cell
membrane and the dying cell does not shrink or form apoptotic bodies
but rather expands in size [16]. Since this parasite-induced cell death
can be inhibited by treatment with the cysteine protease inhibitor E64,
cysteine proteases appear to be key players in this process. We found
considerable amounts of PbICP in the host cell upon PVMbreakdown.
Thus, it can be predicted that the cysteine proteases responsible for cell
death induction belong to the cathepsin-B type that is not targeted by
PbICP. Potential candidates are SERA proteases, a family of parasite-
derived putative cysteine proteases. They are released into the host cell
cytoplasm at the same time as PbICP. Unfortunately, experimental
proof of the hypothesis that PbICP does not inhibit SERA protease
activity is not possible because SERA proteases cannot currently be
recombinantly produced in their enzymatically active state. Why
would the parasite not simply allow the host cell to undergo apoptosis
but instead use its own proteases to induce host cell death? The answer
might be that activation of apoptosis-related proteases such as caspases
and calpain-1 induces a rapid destruction of the cytoskeleton and a
breakdown of the cell into apoptotic bodies or rupture of the host cell
membrane. A rapid destruction of the host cell would result in a
premature release of merozoites before they have been transported
inside merosomes safely into the blood vessels. Merosome formation
and merozoite transport can last for several hours and thus the parasite
needs to maintain control of host cell proteases. On the other hand, the
parasite requires cysteine proteases that induce an ordered but slow
host cell death and allow the formation of merosomes.
To further analyze the function of PbICP translocated into the
host cell cytoplasm, it will be necessary to identify its target
protease. We suggest that PbICP acts on both parasite and host
cell proteases. An effect on host cell proteases has already been
shown for a number of ICPs of other pathogens. A good example
is the prokaryote P. aeruginosa, which expresses a functional
chagasin homolog but no potential target proteases of the C1
protease family [37], suggesting that chagasin-like inhibitors in
general may have evolved to inhibit foreign proteases.
All so-far characterized chagasin-like inhibitors have shown a
significantly lower affinity to cathepsin B than to cathepsin L-like
C1 cysteine proteases [37,58]. For chagasin, it was shown that this
decreased cathepsin B affinity is due to the occluding loop that is in
close proximity to the active site of the protease [58] [71]. In
contrast to the so-far characterized chagasin members of other
organisms, the Plasmodium ICPs show a complete loss of cathepsin
B inhibition [40]. Plasmodium ICPs contain sequence insertions in
the chagasin-like C-terminal domain, which might, in principle,
interfere with cathepsin B binding. A recent publication reports
that T. gondii-derived toxostatins, two other members of the
chagasin family, contain similar extensions as found in the
chagasin-like domain of PbICP. Remarkably, toxostatin-1 was
already shown to retain the capability of inhibiting cathepsin B
[43]. Together with our own data, it can be concluded that the
Figure 9. Possible roles of PbICP during the exoerythrocytic development of P. berghei in vitro. 1: PbICP (green circles) is secreted by free
gliding sporozoites and supports invasion of HepG2 cells. Intracellular sporozoites and trophozoites continue to express and partially secrete PbICP.
Thus PbICP can potentially control parasite-derived cysteine proteases as well as host cell cysteine proteases. 2+3: During schizogony, PbICP is
predominately located in the PV and the parasite cytosol, suggesting that during this developmental phase, parasite cysteine proteases are the main
target of the inhibitor. However, it cannot be excluded that small portions of the inhibitor, which are beyond the detection level for IFA, are still
exported into the host cell cytoplasm. 4: At the end of the liver stage, upon disruption of the PVM, a substantial amount of PbICP is passively released
into the host cell cytoplasm. At this stage, the main function of PbICP might be inhibition of host cell cysteine proteases to allow a slow and ordered
host cell death and merosome formation.
doi:10.1371/journal.ppat.1000825.g009
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lack of cathepsin B inhibition by Plasmodium ICPs is not caused by
an interference of the extension loops with the occluding loop of
the protease but must be due to other structural motifs.
To characterize the function of PbICP, we generated transgenic
P. berghei parasites constitutively over-expressing a GFP-tagged
version of the inhibitor. Although these parasites were very helpful
for analyzing PbICP localization and processing during the liver
stage, the genetic manipulation did not provoke a pronounced
phenotype apart from a slightly better invasion rate. The best
genetic manipulation to analyze the biological function of PbICP
would be to knock out the pbicp gene. This approach has been tried
several times without success, strongly suggesting that PbICP
expression is essential during the blood stage because transfection
and the selection of transgenic parasites is performed at this stage.
In conclusion, we identified a potent cysteine protease inhibitor
of P. berghei that seems to play different roles during the life cycle of
the malaria parasite. In the exo-erythrocytic stage, PbICP is
important for the invasion of sporozoites and is able to protect the
host cell from apoptosis, which is essential for the completion of
liver stage development.
Supporting Information
Figure S1 Multiple sequence alignment of ICPs. Multiple
sequence alignment of PbICP and the ICPs of P. yoelii (PyICP)
and P. falciparum (falstatin/PfICP) in comparison with the ICPs of
T. gondii (toxostatins), T. cruzi (chagasin), T. brucei, L. mexicana and
the two ICPs of E. histolytica. Conserved amino acid residues of the
chagasin inhibitor family are highlighted in grey, the wedge
forming loops that bind the active-site cleft of proteases (L2, L4,
L6) are highlighted in yellow. The amino acid residues of chagasin
highlighted in purple form the b-sheet strands. The N-terminal
residues of PbICP highlighted in pink represent the classic signal
sequence.
Found at: doi:10.1371/journal.ppat.1000825.s001 (0.56 MB PDF)
Figure S2 Multiple sequence alignment of the ICP chagasin
domains. (A) Multiple sequence alignment of the C-terminal
chagasin-like domain of PbICP, PyICP and falstatin/PfICP in
comparison with the ICPs of T. gondii (toxostatins), T. cruzi
(chagasin), T. brucei, L. mexicana and the two ICPs of E. histolytica.
Conserved residues of the chagasin inhibitor family are highlighted
in grey, the wedge forming loops that bind the active-site cleft of
proteases (L2, L4, L6) are highlighted in yellow. At the top of the
alignment the b-strands of chagasin are displayed in purple. The
amino acid sequences of chagasin that form b-strands are
additionally indicated in purple. (B) Known b-strands of chagasin
and predicted b-strands of PbICP are depicted by arrows. In
contrast to chagasin (purple), the inhibitor domain of PbICP
(green) is predicted to have two additional b-strands (b59 and b599)
and elongated loop-structures L3 and L4 (red, dashed line) as well
as a N-terminal extension region with a classic N-terminal signal
sequence (grey). The wedge-forming loops that bind into the active
site cleft of the proteases (L2, L4, L6) are highlighted in yellow.
Like the toxostatins of T. gondii, but in contrast to the non-
apicomplexan chagasin-like inhibitors of other protozoa and
bacteria, the Plasmodium ICPs do not contain the NPTTG motif
in L2 (variable motifs of P. berghei and P. falciparum are shown).
Found at: doi:10.1371/journal.ppat.1000825.s002 (0.31 MB PDF)
Figure S3 Schematic overview of PbICP constructs and epitopes
used for the generation of antisera and examples of specificity
controls. (A) To generate a specific antisera different regions of
PbICP were used to immunize mice and rabbits. A mouse anti-
PbICP antiserum was generated using MBP-tagged full-length
PbICP. Recombinant His-PbICP-CGDEK was used for immuni-
zation to produce PbICP-C domain-specific antisera. Anti-PbICP-
N domain-specific antisera were obtained from mice using
recombinant MBP-PbICP-NSFNH for immunization and from
rabbits using the peptide EDIEDNQKYPTTSYN. Panels (B and
C) show a specificity control of the anti-PbICP-C antiserum
(rabbit) in IEM.
Found at: doi:10.1371/journal.ppat.1000825.s003 (7.94 MB PDF)
Figure S4 Specificity test of anti-PbICP-antiserum directed
against His-PbICP-CGDEK. Confocal images of HepG2 cells
infected with P. berghei wildtype parasites 55 hpi. Preimmune
control (A) and anti-PbICP-C (B). Infected cells were fixed,
incubated with a chicken anti-ExpI antiserum (secondary
antibody: anti-chicken Alexa 594) and a rabbit antiserum against
PbICP-C (secondary antibody: anti-rabbit Cy2) (B) or preimmune
serum (secondary antibody: anti-rabbit Cy2) (A). DNA was stained
with DAPI (blue).
Found at: doi:10.1371/journal.ppat.1000825.s004 (1.67 MB PDF)
Figure S5 Staining of unfixed sporozoites shows PbICP
localization at the apical pole of the sporozoite. Salivary gland
sporozoites expressing mCherry were incubated on ice with rabbit
anti-PbICP-C antiserum (A), rabbit anti-CSP antiserum (B) or
rabbit preimmune serum (C), washed, subsequently stained with
Cy2-conjugated secondary anti-rabbit antibody (green) and
Hoechst 33258 (blue), again washed and immediately analyzed
by fluorescence microscopy.
Found at: doi:10.1371/journal.ppat.1000825.s005 (0.48 MB PDF)
Figure S6 PbICP is secreted by intracellular trophozoites
(confocal IFA). (A) IFA of a GFP-expressing HepG2 cell infected
with P. berghei. Infected cells were fixed 4 hpi, incubated with
polyclonal antisera against PbICP-C (rabbit) and against GFP
(mouse) and subsequently stained with fluorescently labeled
secondary antibodies (anti-rabbit, red and anti-mouse, green).
DNA was stained with DAPI (blue). Partial co-localization of
PbICP and GFP confirmed secretion of the inhibitor in the host
cell cytoplasm. (B) Quantitative analysis of PbICP secretion. IFA of
a HepG2 cell infected with P. berghei. Infected cells were fixed 4
hpi, incubated with polyclonal antiserum against PbICP-C (rabbit)
and against CSP (mouse) and subsequently stained with fluores-
cently labeled secondary antibody (anti-rabbit conjugated with
Cy2, green and anti-mouse conjugated with Alexa594, red). DNA
was stained with DAPI (blue). Parasites associated with HepG2
cells and found in the same focal plane as the host cell nucleus
were considered intracellular (see typical confocal images in
inserts). Intracellular parasites were counted and the absolute
numbers of parasites secreting either PbICP and CSP or CSP
alone are shown in the graph.
Found at: doi:10.1371/journal.ppat.1000825.s006 (1.76 MB PDF)
Figure S7 PbICP is secreted by intracellular sporozoites (wide-
field IFA). IFA of HepG2 cells infected with P. berghei (cytosolic
mCherry expression, red) 2 hours after infection. Infected cells
were fixed, incubated with polyclonal antiserum against PbICP-C
(rabbit) and subsequently stained with fluorescently labeled
secondary antibody (anti-rabbit conjugated with Cy2, green).
DNA was stained with DAPI (blue).
Found at: doi:10.1371/journal.ppat.1000825.s007 (1.61 MB PDF)
Figure S8 PbICP partially co-localizes with the PVM marker
ExpI at the schizont stage (confocal IFA). Confocal IFA of P.
berghei-infected HepG2 cells. Cells were fixed 30 hpi and stained
with polyclonal antisera against PbICP-C (rabbit, red) and ExpI
(chicken, green). DNA was stained with DAPI (blue).
Found at: doi:10.1371/journal.ppat.1000825.s008 (0.35 MB PDF)
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Figure S9 PbICP localizes to vesicular structures in the PV of
liver stage schizonts. IFA of HepG2 cells infected with P. berghei at
48 hpi. Infected cells were fixed and stained with anti-ExpI
antiserum (chicken, red) and polyclonal antiserum against PbICP-
C (rabbit, green). DNA was stained with DAPI (blue). Represen-
tative images are presented in A-D.
Found at: doi:10.1371/journal.ppat.1000825.s009 (2.00 MB PDF)
Figure S10 PbICP is released into the host cell cytoplasm at the
end of the liver stage. IFA of HepG2 cells infected with P. berghei at
the end of the liver stage (63 hpi) prior to and after visible
destruction of the PVM. Infected cells were fixed, stained with
DAPI (A) and with anti-ExpI antiserum (chicken, red) and
polyclonal antiserum against PbICP-C (mouse, green) (B).
Different phenotypes are presented as a cartoon (C). Late
schizont/merozoite stages were counted and the percentage of
each different phenotype was calculated. Presented on top of the
images are the means and standard deviations of three
independent experiments (frequency of phenotypes). Main phe-
notypes are parasites with intact PVM and PbICP restricted to the
parasite and the PV, and parasites with disrupted PVM visible by
Exp1 staining and PbICP release into host cell cytoplasm. hc: host
cell.
Found at: doi:10.1371/journal.ppat.1000825.s010 (3.02 MB PDF)
Figure S11 Characterization of the PbICP-GFP-expressing liver
stage parasites. (A-E) Live imaging of PbICP-GFP-expressing liver
stage parasites confirmed the PbICP localization determined by
the antisera-based analysis. HepG2 cells were incubated with
PbICP-GFP-expressing P. berghei parasites and analyzed at
different time points after infection. The sporozoite shown in
panel (A) revealed an apical accumulation of the GFP fluorescence
(marked with an asterisk). Early liver stage parasites (B) released
GFP-positive structures (marked with arrows). In schizont stages
(C, D), GFP fluorescence was found in the PV and the parasite
cytosol. At the end of the liver stage, after detachment of the
infected HepG2 cell (E), GFP fluorescence was found in the host
cell cytoplasm and in the merozoites.
Found at: doi:10.1371/journal.ppat.1000825.s011 (3.78 MB PDF)
Figure S12 PbICP-GFP-expressing P. berghei show slightly
enhanced infection efficiency. HepG2 cells were infected with
transgenic PbICP-GFP sporozoites or GFPcon sporozoites as a
control, incubated for 1 h, subsequently fixed without permeabi-
lization and stained with an anti-CSP antiserum (inside/outside
assay). Extracellular but not intracellular sporozoites were labeled
by the anti-CSP antiserum. Intracellular sporozoites are only
positive for GFP expression. Sporozoites were counted and the
percentages of free and intracellular sporozoites were calculated.
Presented are the means and standard deviations of three
independent experiments.
Found at: doi:10.1371/journal.ppat.1000825.s012 (0.09 MB PDF)
Figure S13 PbICP-GFP expressing parasites do not differ in
their intrahepatic development from mCherry-expressing para-
sites. HepG2 cells were infected with transgenic PbICP-GFP
sporozoites or mCherry-expressing sporozoites. Parasite size was
determined over the course of development in HepG2 cells using
the density slice module of the OpenLab 5.03 software. Size was
measured at 24, 48 and 63 hpi by live imaging. Since mCherry
expression is restricted to the parasite cytosol but PbICP-GFP is
also translocated into the PV, PbICP-GFP-expressing parasites
appear slightly bigger (upper panel). To analyze this observation in
more detail, infected cells were fixed and stained with an anti-
Exp1 antiserum, which labels the PVM of both parasite strains
(lower panel). In contrast to the live imaging, this experiment
revealed that mCherry parasites are slightly bigger confirming that
PbICP-GFP is secreted into the PV.
Found at: doi:10.1371/journal.ppat.1000825.s013 (0.38 MB PDF)
Figure S14 PbICP-C expression protects HepG2 cells against
host cell death (camptothecin treatment). (A) HepG2 cells were
transiently transfected with a plasmid leading to cytosolic
expression of GFP-tagged PbICP-C (upper panel) or with a GFP
control plasmid (lower panel). Subsequently host cell death was
induced by camptothecin treatment for 24 h and analyzed by live
imaging of intact mitochondria by TMRE (red) and DNA by
Hoechst (blue). Dying cells exhibited condensed chromatin in the
nucleus and a loss of mitochondrial membrane potential. (B)
Fluorescent cells were counted and the percentages of dead and
viable cells were calculated. Cells expressing GFP-PbICP-C
showed significantly better survival upon camptothecin-induced
cell death in comparison to GFP-expressing cells.
Found at: doi:10.1371/journal.ppat.1000825.s014 (1.28 MB PDF)
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